PBYI Stock Risk & Deep Value Analysis
Puma Biotechnology Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About PBYI Stock
We analyzed Puma Biotechnology Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran PBYI through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
PBYI Risk Analysis & Red Flags
What Could Go Wrong
The primary revenue driver, NERLYNX, continues its decline in new prescriptions, leading to sustained revenue contraction and further earnings degradation. Without new pipeline catalysts or a significant strategic pivot, the company may fail to generate meaningful shareholder value, despite its positive cash flow.
Risk Matrix
Overall
Aggressive
Financial
Medium
Market
Medium
Competitive
High
Execution
High
Regulatory
Medium
Red Flags
- ⚠
Previous Q1 2026 guidance projected significant revenue decline and net loss (as per prior analysis).
- ⚠
New prescriptions for NERLYNX are reportedly declining (as per prior analysis).
- ⚠
Proposed extension of CEO Alan Auerbach's warrant for 2.1M shares, potentially diluting shareholder value.
- ⚠
Absence of clear new growth catalysts or strategic initiatives to drive 10x growth.
Upcoming Risk Events
- 📅
Disappointing Q1 2026 financial results, especially further revenue decline
- 📅
Negative outcome for CEO warrant vote or significant shareholder discontent
- 📅
Continued decline in NERLYNX new prescriptions and sales
When to Reconsider
- 🚪
Quarterly revenue consistently drops below $70M.
- 🚪
Significant further deterioration in NERLYNX new prescription trends or market share.
- 🚪
Failure of management to articulate a credible growth strategy or deliver on turnaround efforts.
Unlock PBYI Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Puma Biotechnology Inc (PBYI) Do?
Market Cap
$382.10M
Sector
Healthcare
Industry
Biotechnology
Employees
172
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Visit Puma Biotechnology Inc WebsiteInvestment Thesis
Puma Biotechnology represents a highly speculative deep-value or turnaround investment. The thesis relies on the company's ability to stabilize NERLYNX sales, potentially through new indications or market strategies, or for a dormant pipeline asset (like Alisertib) to emerge as a viable growth driver. Its strong balance sheet and positive free cash flow provide a runway for these efforts, while its low valuation multiples (P/S) offer potential upside if a turnaround materializes.
Is PBYI Stock Undervalued?
Unlock the full AI analysis for PBYI
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
PBYI Price Targets & Strategy
12-Month Target
$8.90
Bull Case
$11.88
Bear Case
$5.29
Valuation Basis
Based on 1.5x P/S multiple applied to annualized trailing revenue of ~$302M.
Entry Strategy
Consider dollar-cost averaging near current levels ($7.00-$7.50) if the Q1 2026 earnings report shows stabilization or less severe decline than anticipated.
Exit Strategy
Take profit at $10.00-11.50 if catalysts emerge and execution improves. Implement a stop loss below $6.50 if NERLYNX sales continue to decline significantly.
Portfolio Allocation
1-3% for aggressive risk tolerance, as a highly speculative turnaround play.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is PBYI Financially Healthy?
Valuation
P/E Ratio
12.28
Forward P/E
11.55
EV/EBITDA
4.67
PEG Ratio
0.01
Price/Book
2.25
Price/Sales
0.98
Profitability
Gross Margin
74.53%
Operating Margin
16.33%
Net Margin
13.62%
Return on Equity
27.81%
Revenue Growth
-0.91%
EPS
$0.61
Balance Sheet
Current Ratio
2.00
Quick Ratio
1.89
Debt/Equity
0.17
Cash Flow
EBITDA
$57.34M
Other
Beta (Volatility)
1.27
Does PBYI Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Eroding
Moat Sources
1 Identified
The moat is primarily derived from NERLYNX's regulatory approval and intellectual property, which offer protection for a period. However, its durability is eroding due to increasing competition, potential for more effective therapies, and the observed decline in new prescriptions.
Moat Erosion Risks
- •Emergence of superior or more cost-effective therapies from competitors.
- •Patent expiry or loss of exclusivity for NERLYNX.
- •Limited success in expanding NERLYNX's indications or developing new pipeline assets.
PBYI Competitive Moat Analysis
Sign up to see competitive advantages
PBYI Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral, with no specific social media momentum reported.
Institutional Sentiment
Neutral. One analyst holds a 'Hold' rating, while Wall Street Zen upgraded to 'strong-buy' on March 21, 2026. Institutional ownership is around 61%.
Insider Activity (Form 4)
On April 1, 2026, the Compensation Committee granted 31,625 inducement RSUs to 5 new non-executive employees, vesting over 3 years. No other insider purchases or sales by executive officers were reported in the last 90 days. The proposed extension of the CEO's warrant to Oct 4, 2028, is a significant future potential insider action.
Options Flow
Normal options activity; no specific unusual options flow was identified in the research data.
Earnings Intelligence
Next Earnings
2026-05-07
Surprise Probability
Medium (Q4 2025 EPS beat consensus, but Q1 2026 guidance was previously reported as negative, creating uncertainty).
Historical Earnings Pattern
No specific historical earnings reaction patterns were provided in the research; expect volatility given the current state.
Key Metrics to Watch
Competitive Position
Top Competitor
Genentech (Roche) / AstraZeneca (larger players in breast cancer oncology)
Market Share Trend
Losing ground in the HER2+ breast cancer segment, as evidenced by declining new prescriptions for NERLYNX (based on prior analysis).
Valuation vs Peers
PBYI trades at a significant discount to sector peers on a P/S basis (1.0x vs. sector 3.3x), but its forward P/E (based on FY26 consensus EPS of $0.14) is likely very high due to earnings contraction, making direct P/E comparison challenging.
Competitive Advantages
- •Approved drug (NERLYNX) with established market presence for specific HER2+ breast cancer indications.
- •Intangible assets in the form of intellectual property and regulatory approvals.
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive PBYI Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Release and Conference Call (May 7, 2026)
- •Shareholder vote on CEO Alan Auerbach warrant extension (June 11, 2026 annual meeting)
Medium-Term (6-18 months)
- •Stabilization or modest recovery in NERLYNX new prescriptions
- •Potential positive clinical data from Alisertib (if announced)
Long-Term (18+ months)
- •New indications for NERLYNX or other pipeline asset approvals
- •Strategic acquisition interest from larger pharmaceutical companies
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for PBYI?
- ✓
Acceleration or stabilization in NERLYNX revenue growth and new prescription trends.
- ✓
Announcement of positive clinical trial data for pipeline candidates, particularly Alisertib.
- ✓
Improved clarity on strategic vision and execution from management to re-ignite growth.
Bull Case Analysis
See what could go right with Premium
Competing with PBYI
See how Puma Biotechnology Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Puma Biotechnology Inc PBYI | $382.1M | 2.0 | 12.3 | $238.1M | 13.6% | -0.9% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Puma Biotechnology Inc Makes Money
Puma Biotechnology Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of cancer. Its primary source of revenue comes from the sales of its flagship product, NERLYNX (neratinib), an oral medication used for certain types of HER2-positive breast cancer. The company generates revenue by selling this drug to healthcare providers who prescribe it to eligible patients, managing distribution, and supporting its clinical use.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Puma Biotechnology Inc (PBYI)?
As of April 28, 2026, Puma Biotechnology Inc has a DVR Score of 2.0 out of 10, placing it in the "Risk Trap" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Puma Biotechnology Inc?
Puma Biotechnology Inc's market capitalization is approximately $382.1M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Puma Biotechnology Inc use?
PBYI is the ticker symbol for Puma Biotechnology Inc. The company trades on the NMS.
What is the risk level for PBYI stock?
Our analysis rates Puma Biotechnology Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of PBYI?
Puma Biotechnology Inc currently has a price-to-earnings (P/E) ratio of 12.3. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Puma Biotechnology Inc's revenue growing?
Puma Biotechnology Inc has reported revenue growth of -0.9%. Revenue has been declining, which warrants closer examination.
Is PBYI stock profitable?
Puma Biotechnology Inc has a profit margin of 13.6%. The company is profitable but margins are modest.
How often is the PBYI DVR analysis updated?
Our AI-powered analysis of Puma Biotechnology Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 28, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for PBYI (Puma Biotechnology Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.